LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies to treat inflammatory dry eye disease (DED), a multi-billion dollar market, and anterior segment diseases including neuropathic corneal pain (NCP), an eye disease associated with pain but for which there is no FDA-approved therapy, today announced that an interview with its CEO, Dr. Gary S. Jacob, will air on The RedChip Small Stocks, Big Money™ on Bloomberg TV this Saturday, August 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes in the U.S.

In an exclusive interview, Gary S. Jacob, PhD, CEO of OKYO Pharma, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a company update. OKYO is a clinical-stage biopharmaceutical company developing innovative therapies to treat dry eye disease (DED) and neuropathic corneal pain (NCP), two areas of significant unmet medical need. OKYO’s lead candidate, OK-101, utilizes a unique lipid-conjugated chemerin peptide and is designed to treat inflammation and pain more effectively than current treatments. The recent Phase 2 study in DED demonstrated remarkable improvements in both symptoms and signs in just 15 days, with a favorable safety profile and no drug-related serious adverse events. In addition, OK-101 also offers a significant opportunity to treat the eye disease NCP, for which there is no FDA-approved drug to treat patients with this acute, chronic eye disease. OKYO’s robust patent protection until at least 2039 and an experienced management team with proven success in clinical development through to FDA approval underline the company’s strong positioning for future growth in ophthalmology.

A replay will be available in the Investor Media section of the Company’s website. https://okyopharma.com/media/

About OK-101
OK-101 is a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein-coupled receptor typically found on ocular immune cells responsible for the inflammatory response. OK-101 was developed using membrane-anchored peptide technology to produce a novel long-acting drug candidate for the treatment of dry eye. OK-101 has been shown to generate anti-inflammatory and analgesic efficacy signals in mouse models of dry eye and corneal neuropathic pain (NCP), respectively, and is designed to prevent washout through the inclusion of the lipid anchor built into the drug molecule to prolong the residence time of OK-101 in the ocular milieu. OK-101 recently demonstrated statistical significance in multiple endpoints in a recently completed multicenter, double-blind, placebo-controlled Phase 2 study of OK-101 for the treatment of DED.

About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies to treat DED and NCP. Its common stock is listed for trading on the NASDAQ Capital Market. OKYO is focused on discovering and developing novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 trial in DED, OKYO also plans to initiate a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For more information, visit www.okyopharma.com.

Inquiries: